Page last updated: 2024-09-05

sorafenib and ovatodiolide

sorafenib has been researched along with ovatodiolide in 2 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(ovatodiolide)
Trials
(ovatodiolide)
Recent Studies (post-2010) (ovatodiolide)
6,5207305,25131025

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Bamodu, OA; Chang, HL; Chen, HA; Lee, KF; Lee, WH; Tsai, JT; Tzeng, YM1
Chen, MY; Chu, YC; Hsieh, MS; Hsu, CH; Ma, HP; Ong, JR; Setiawan, SA; Tzeng, DTW; Tzeng, YM; Wu, ATH; Yeh, CT1

Other Studies

2 other study(ies) available for sorafenib and ovatodiolide

ArticleYear
Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.
    Toxicology in vitro : an international journal published in association with BIBRA, 2018, Volume: 51

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinoma, Hepatocellular; Diterpenes; Endoplasmic Reticulum Chaperone BiP; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Phosphoproteins; Sorafenib; Transcription Factors; YAP-Signaling Proteins

2018
Ovatodiolide and antrocin synergistically inhibit the stemness and metastatic potential of hepatocellular carcinoma via impairing ribosome biogenesis and modulating ERK/Akt-mTOR signaling axis.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023, Volume: 108

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Diterpenes; Humans; Lactones; Liver Neoplasms; Mice; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Ribosomes; Sesquiterpenes; Sorafenib; TOR Serine-Threonine Kinases

2023